Sorafenib shows broader anti AML cell activity than Imatinib or Sunitinib

Posted on May 15, 2008 by crimsoncanary

In vitro analysis of multikinas inhibitors imatinib, sorafenib, and sunitinib in human AML cell lines show sorafenib to inhibit the most blast samples

Filed under: kinase | Tagged: , , , , , , , , , , , , , ,

« Scientists from H Lee Moffitt describe Rb/Raf-1 inhibitors ASCO abstracts available for search »

Leave a Reply